Genomic
Sequence Quantification

ⓖSEQ is our exclusive method for the amplification and sequencing of DNA from embryo biopsies. This method provides an unparalleled ability to accurately quantify chromosomes for aneuploidy screening, as well as genotype single-gene and polygenic disorders.
Compared to the leading aneuploidy screens on the market, ⓖSEQ is:
  • Less expensive.
  • Less error-prone.
  • Significantly easier to perform.
$150/case, $200/embryo
Learn More
Order

Expanded
Pre-Implantation Genomic Testing

EPⓖT enables the routine, inexpensive evaluation of hundreds of thousands of genetic variants through a novel combination of embryo genotyping methods. Among the genetic disorders whose phenotype risk can routinely be diagnosed by EPⓖT are:
  • 300+ common single-gene disorders, such as Cystic Fibrosis, Thalassemia, BRCA, Sickle Cell Anemia, and Gaucher Disease
  • Polygenic Disease Risk, such as risk for Type 1 and Type 2 diabetes, Dwarfism, Hypothyroidism, Mental Disability, Atrial Fibrillation and other Cardiovascular Diseases like CAD, Inflammatory Bowel Disease, and Breast Cancer.
$1000/case, $400/embryo
Learn More

Why Choose
Genomic Prediction?

Genomic Prediction provides advanced genetic testing for IVF. We have developed a novel, genome-wide molecular genotyping methodology for pre-implantation genetic testing of embryos.

Our approach reduces disease risk and improves newborn health outcomes by identifying candidate embryos for implantation which are genetically normal.

MONOGENIC

(of human disease)

POLYGENIC

(of human disease)

What the World Says

In 2019, [IVF Couples using EPⓖT] will have an opportunity to give their offspring a greater chance of living a long and healthy life.

The Economist's "The World of 2019"

I take my hat off to what they’re doing, it’s a potential revolution.

Simon Fishel,
president of the Care Fertility Group
clinics in the UK

Latest News

German-language Feature in Die Welt

Genomic Prediction has been featured in Die Welt, under the title "Werden Embryonen bald nach Intelligenz aussortiert?", published in the aftermath of He Jiankui's CRISPR baby announcement. A translated article follows.
Genomic Prediction feature: Psychology Today

The interview by Marty Nemko, Ph.D. is titled "The Future of In-Vitro Fertilization and Gene Editing". Following an interview of Harvard's Prof. George Church, this latest interview in PT's "The Eminents" asks Prof. Hsu about neurogenetic screening.
Dr. Treff's Validation Presentation on EPⓖT

Chief Science Officer of Genomic Prediction, Dr. Nathan Treff, presents at American Society for Reproductive Medicine on "Validation of simultaneous preimplantation genetic testing (PGT) for aneuploidy, monogenic, and polygenic disorders"
Genomic Prediction featured in New Scientist

Clare Wilson's piece is titled: "Exclusive: A new test can predict IVF embryos’ risk of having a low IQ: A new genetic test that enables people having IVF to screen out embryos likely to have a low IQ or high disease risk could soon become available in the US"
Genomic Prediction featured in the Economist

Journalist Ananyo Bhattacharya's article is titled "Baby Steps: A slippery slope towards designer babies?". This article appears in "The World in 2019", The Economist's annual edition, looking at the year ahead. Available on newsstands now.
Genomic Prediction featured in WSJ Podcast

The award winning podcast of the Wall Street Journal, "The Future of Everything", features Genomic Prediction, as well as the BGI Shenzhen Cognitive Genomics Laboratory, exploring the ethics of embryo screening for polygenic risk.
EPⓖT Approved by NJ Department of Health

September 2018 Marks the approval of Genomic Prediction's PGT-M (Preimplantation Genetic Test for Monogenic Disorders) and PGT-P (Preimplantation Genetic Test for Polygenic Disorders) tests, meeting the IVF medical standards of the DOH.
Genomic Prediction in the Wall Street Journal

WSJ Journalist Amy Dockser Marcus has a new article out titled "Is It Ethical to Choose Your Baby’s Eye Color?", exploring the technical capabilities of the state of the art (Genomic Prediction), and the ethical questions raised by embryo selection in general.
Genomic Prediction approved by Maryland DOH

The Maryland Department of Health (DOH) Office of Health Care Quality represents the highest standard of laboratory quality assurance for Maryland. Genomic Prediction have been granted a full, non-expiring Medical Laboratory Permit.
Dr. Prof. Stephen Hsu interviewed on AirTalk

Reproductive medicine has long been used to learn about a child’s health. Famed radio host Larry Mantle interviews Dr. Hsu, alongside Josephine Johnston, director of the Hastings Center bioethics research institute, to explore genetic testing of embryos.

Got questions?
We're here to help!

© Genomic Prediction, 2018